Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Walgreens

DEERFIELD, Ill. & IRVING, Texas--(BUSINESS WIRE)--WBA, McKesson announce WBA to acquire the remaining 30% share of their GEHE Pharma Handel (GEHE) & Alliance Healthcare Deutschland (AHD) joint venture

Walgreens Boots Alliance Acquires Remaining Stake in German GEHE-Alliance Healthcare Joint Venture From McKesson

The shares of McKesson Corporation (NYSE: MCK) have received a $270 price target from Argus. These are the details.

McKesson (MCK) Stock: $270 Price Target From Argus

Labcorp Holdings Inc

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing These Medical Stocks Right Now?

Cardinal Health

West Pharmaceutical Services

Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

3 Promising Stocks From the Buoyant Dental Supplies Industry

AmerisourceBergen

A Washington state trial against McKesson Corporation (NYSE: MCK), Cardinal Health Inc (NYSE: CAH), and AmerisourceBergen Corp (NYSE: ABC) for the U.S. opioid epidemic is slated to kick off today, Reuters reported. Washington Attorney General Bob Ferguson declined to join a $26 billion nationwide settlement and has accused the drug distributors of creating a public nuisance by failing to prevent the diversion of prescription pills into illegal channels.

McKesson, Cardinal Health, AmerisourceBergen Face $95B Opioid Trial In Washington: Reuters

A trial pitting Washington state against McKesson Corp and two other drug distributors accused of fueling the U.S. opioid epidemic is slated to kick off on Monday, after the state's attorney general declined to join a $26 billion nationwide settlement.

McKesson, drug distributors face $95 billion opioid trial in Washington state

Based on a forecast annual return of 4.9% and risk of 24%, McKesson is a Hold. Both EBIT margin and price-to-sales multiple should expand as company shifts focus from opioid litigation and international operation asset sales towards oncology and biopharma services.

McKesson: Oncology Should Drive Higher Margins And Valuation

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation has opened a new pharmaceutical distribution center in Holt, Mich., seven miles south of Lansing. The facility will add more than 80 full-time jobs to the region, including day and night shifts offering competitive pay and benefits. “It is my pleasure to welcome McKesson to the Lansing area as we have a shared focus on creating meaningful jobs for the district,” shared Senator Curtis Hertel, Jr. “We look forward to having them as a valuable a

McKesson Opens State-of-the-Art Distribution Center in Michigan

McKesson's (MCK) fiscal second-quarter 2022 results benefit from substantial growth in the Medical-Surgical Solutions business.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q2

AbbVie

Aflac

Franklin Resources

Hormel Foods

Johnson & Johnson

Medtronic

NextEra Energy

Procter & Gamble

V.F.

S&P 500 dividend aristocrats possess pretty safe dividends. All 65 of them have paid out higher disbursements for at least 25 straight years. We decided to put together our Buy list for the top six to purchase right now.

The Dividend Aristocrat 6-Pack Buy List

McKesson Corp (NYSE: MCK)  reported second-quarter FY22 adjusted EPS of $6.15, +28% Y/Y, and easily beating the analyst consensus of $4.66. Revenues increased 9% Y/Y to $66.57 billion, surpassing the consensus of $63.12 billion, driven by growth in the U.S. Pharmaceutical segment, primarily due to increased specialty volumes and market growth, partially offset by branded to generic conversions.

McKesson Posts Better Than Expected Q2 Earnings; Raises FY22 EPS Outlook Again

McKesson Corporation (MCK) Q2 CEO Brian Tyler on 2022 Results - Earnings Call Transcript

McKesson (MCK) delivered earnings and revenue surprises of 31.69% and 6.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Beats Q2 Earnings and Revenue Estimates

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2022 second-quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Monday, November 1st at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and

McKesson Reports Fiscal 2022 Second-Quarter Results

Amgen

Alibaba

Baidu

JD.com

Reckitt Benckiser Group PLC

SPDR S&P 500 ETF Trust

Tencent Holdings Limited

The stock market in the United States is extremely overvalued but we can find bargains in other countries. Especially tech stocks in China seem extremely cheap and Great Britain is also presenting some picks.

Hunting For Bargains Again: 9 Picks

CBRE Group

D.R. Horton

Kimberly-Clark

Oracle

Sysco

AT&T

Tesla

Texas Instruments

Waste Management

A recent article in Fox Business discussed Tesla's move to Texas from California. Here are 10 stocks to buy based in the Lone Star State.

10 Top Texas Stocks to Buy That Don't Rely On Oil And Gas For Big Gains

McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

McKesson (MCK) to Report Q2 Earnings: What's in the Cards?

McKesson reported solid quarterly results and is also expecting high growth rates for fiscal 2022 (according to the company's guidance). The company undeniably played a role in the opioid crisis and will have to pay $7.9 billion over the next 18 years.

McKesson: Deeply Undervalued Despite $7.9 Billion Settlement

Bank of China Ltd

Cigna

China Construction Bank Corp

Glencore PLC

Honda

China Life Insurance Co. Ltd.

Ping An Insurance Group Co of China Ltd

Sinopec Shanghai Petrochemical

China Petroleum & Chemical

Toyota Motor

Verizon

Walmart

Exxon Mobil

August/September Fortune published the latest 500 "world's largest companies globally in 2020" (based on revenues) and 33 pay dividends. "A pandemic couldn't disrupt the top spot on the Fortune Global 500 for 2020. Mega-retailer, Walmart landed at number one on the list of the world's largest companies," Fortune states.

8 Of The Top 10 Global Fortune 500 Dividend Dogs Are Ideal In October

Cardinal Health Inc (NYSE: CAH), McKesson Corporation (NYSE: MCK), and AmerisourceBergen Corp (NYSE: ABC), accused of U.S. addiction crisis, have struck a settlement with a tribal government, Reuters reports. As part of the deal with Cherokee Nation's territory in Oklahoma, the three companies will pay $75 million over six and half years to resolve claims linked to the opioid epidemic in the region.

Drug Distributors Ink First Opioid Settlement With Cherokee Nation

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2022 financial results after market close on Monday, November 1, 2021. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings press release, financial tables, and slid

McKesson Corporation to Announce Second Quarter Fiscal 2022 Results on November 1, 2021

Adobe

Cintas Corp

FedEx

JPMorgan Chase & Co

Micron Technology

Recent updates on the revisions trends have been somewhat disconcerting, as you can see in the chart below that tracks the evolution of Q3 earnings growth expectations.

Making Sense of the Q3 Earnings Picture and Beyond

News for McKesson Stock (MCK)